Search

Your search keyword '"Drug approval -- Technology application"' showing total 35 results

Search Constraints

Start Over You searched for: Descriptor "Drug approval -- Technology application" Remove constraint Descriptor: "Drug approval -- Technology application" Publisher right vision media Remove constraint Publisher: right vision media
35 results on '"Drug approval -- Technology application"'

Search Results

2. Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO(r)|DARZALEX(r) (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma

3. Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO(r)|DARZALEX(r) as subcutaneous monotherapy for high-risk smoldering multiple myeloma

4. Sleep Specialists and Industry Leaders Converge at HoneyNaps Symposium

5. AI Meets Regulation: Element's RegNav Revolutionizes Medical Device Compliance

6. Finland is applying for more than 81 million euros in EU funding for five digital initiatives

7. ProLynx Announces a Publication Proposing that a Long-Acting Prodrug of SN-38 Could be Effective in Treating Sacituzumab Govitecan-Resistant Tumors

8. Halozyme Announces Takeda Receives FDA Approval for HYQVIA(r) Co-formulated with ENHANZE(r) as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

9. Terran Biosciences Receives Notice of Allowance for Four US Patents Including for the World's First New Salts

10. RetinalGeniXtm Technologies files two provisional patent applications

11. Alucent Biomedical Receive Regulatory Approval for Second U.S. Clinical Study

12. The FDA has granted approval to GE HealthCare for Allia IGS Pulse, the latest iteration of image-guided systems tailored for superior cardiac imaging

13. Xenex Makes De Novo Petition to FDA for LightStrike UV Room Disinfection Technology

14. First Patient Enrolled in Stage 2 of Pivotal Study of SetPoint Medical's Pioneering Technology for the Treatment of Rheumatoid Arthritis

15. PerkinElmer's Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

16. Verismo Therapeutics Announces Submission of IND Application to the FDA for SynKIR-110, a KIR-CAR T-cell Immunotherapy Candidate

17. Esaote North America installs the first Magnifico Open MRI system in Tennessee

18. Glassbox and DiRx have teamed up to advance digital healthcare solutions

19. Philips has received FDA approval for its most advanced acute patient monitoring (510(k))

20. The FDA approves Hemolung(r) as a new drug

21. NEOTENY Achieves World's Top Three Certifications for its Antiviral Film ACLIV Killing COVID-19 Virus by 99.9% Within 30 Minutes

22. ANANDA Scientific's Liquid Structure Cannabidiol (CBD) to Be Clinically Evaluated for Opioid Use Disorder

23. Neuren Pharmaceuticals Limited: Neuren receives feedback on IND for Angelman syndrome and submits IND application for NNZ-2591 in Pitt Hopkins syndrome

24. The AM Titanium Lumbar Interbody BEE(r) PLIF from NGMedical GmbH has been approved by the FDA

25. Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003

26. Nexus Pharmaceuticals Receives Patent for EMERPHED(r) Ready-To-Use Ephedrine Sulfate Injection

27. HAGAR Secures $11.7M Series B Funding to Advance Non-Invasive Blood Glucose Monitoring Technology

28. Galderma Receives FDA Approval for Restylane(r) Contour for Cheek Augmentation and Correction of Midface Contour Deficiencies

29. Blue Prism and ibi to Fast Track Covid-19 Vaccine Management

30. Advanced Accelerator Applications Receives FDA Approval for Lutathera(r) for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

31. NOVARTIS AG CHF0.50(REGD) Advanced Accelerator Applications Receives FDA Approval for Lutathera(r) for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

32. Advanced Accelerator Applications Receives FDA Approval for Lutathera(r) for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

33. Advanced Accelerator Applications Receives FDA Approval for Lutathera(r) for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

34. Advanced Accelerator Applications Receives FDA Approval for Lutathera(r) for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

35. Advanced Accelerator Applications Receives FDA Approval for Lutathera(r) for Treatment of Gastroenteropancreatic Neuroendocrine Tumors

Catalog

Books, media, physical & digital resources